Drugs / T cell injection targeting B7-H3 chimeric antigen receptor
T cell injection targeting B7-H3 chimeric antigen receptor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05562024 | Dec 2022 → Dec 2025 overdue | — | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T cell injection targeting B7-H3 chimeric antigen receptor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05562024 ↗ |